Aroa Biosurgery (ARX) investor relations material

Opening remarks and agenda

• Introductions and meeting agenda outlined, including financial review, Q&A, and formal business resolutions.

• Instructions provided for submitting questions and participating in the meeting.

• Meeting commenced with a welcome and brief introduction, setting the stage for the AGM proceedings.

Financial performance review

• Revenue grew 23% to NZD 104 million in FY26, with normalized EBITDA reaching NZD 13 million and NZD 5 million in cash generated.

• Myriad sales increased 54% at over 85% gross margin, now contributing nearly 60% of revenues.

• Ovitex sales grew by 8%, supported by strong clinical evidence and ongoing trials.

• Operating cash flow reached NZD 10 million, ending the year with NZD 27 million in cash and no debt.

• FY27 revenue guidance set at NZD 115–125 million (13–23% growth), with direct revenue expected to grow 24–40% and significant investments in sales and commercial infrastructure.

Board and executive committee updates

• John Pinion and John Diddams retired from the board; Paul Shearer joined as non-executive director, bringing extensive global healthcare experience.

• Michael Lynskey recruited as Chief Commercial Officer to support international growth.

• CEO and Managing Director emphasized the mission to unlock regenerative healing and highlighted strategic product advancements.